Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

Ascendis Pharma的YORVIPATH現在在美國正式推出，用於治療成人低甲狀旁腺功能減退症。

Benzinga · 2024/12/19 07:42

Ascendis Pharma A/S (NASDAQ:ASND) today announced that YORVIPATH (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.

Ascendis Pharma A/S（納斯達克股票代碼：ASND）今天宣佈，YORVIPATH（palopegteriparatide；開發名爲TransCon PTH）現已在美國通過處方上市。YORVIPATH是甲狀旁腺激素（PTH [1-34]）的前藥，每天給藥一次，旨在在24小時給藥期內持續暴露於活性甲狀旁腺激素。它是美國食品藥品監督管理局（FDA）批准的第一種也是唯一一種用於治療成人甲狀旁腺功能減退的藥物。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

風險及免責聲明

聲明